juni 2023

Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients

New data presented at EHA23 indicates the potential of gilteritinib in eradicating minimal residual disease and its implications for improving outcomes in high-risk AML patients.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Få adgang
Hvis du allerede har en profil: Log ind

Relateret indhold

Cytarabine Dose Intensification Improves Survival in Older Patients with AML

december 2024 / Gunnar Juliusson

AML 08:21

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

november 2024 / BestPractice Nordic

EHA24 AML

Functional Characterization for Germline Variants in Patients with MDS and AML

juni 2024 / Nikolaj Juul Nitschke

EHA24 AML 03:17

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

januar 2024 / Sigrid S. Skånland

AML CLL

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

december 2023 / Jad Othman

ASH23 AML 03:32

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

december 2023 / BestPractice Nordic

ASH23 AML

In the Era of Personalized Treatment and Targeted Therapies

december 2023 / Sergio Giralt

ASH23 AML 2:46

Overlevelsesgevinst for skrøbelige CLL-patienter i behandling med Imbruvica og Venclyxto

september 2023 / Carsten Utoft Niemann

EHA23 CLL 3:35

Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma

august 2023 / Anna Sureda Balari

EHA23 Lymfom 6:24

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen